# US 11,078,256 B2 · Methods and compositions for inhibiting cancer cell growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,256 B2
- Document ID: US11078256B2
- Status: Granted
- Kind: B2
- Application number: 16/452,178
- Filed: 2019-06-25
- Published: 2019-12-26
- Granted: 2021-08-03
- Earliest claimed: 2018-06-26
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of the University of Texas System
- Inventors: Charles F. Streckfus
- Web page: https://patentgrep.com/patent/US11078256B2

## CPC

- C07K 14/47: from mammals
- C07K 14/8146: {Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are methods and compositions that provide for generating synthetic or recombinant proline rich peptides. In some aspects, p1978 compositions are used to inhibit breast cancer cell growth and thus provided is a method for treating and preventing breast cancer cell growth in a mammal.

## Claims

### Claim 1

A method of treating or preventing a cancer in a subject comprising administering an effective amount of a composition comprising a recombinant polypeptide comprising the amino acid sequence of p1978 (SEQ ID NO: 1).

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is a breast cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the breast cancer is triple negative breast cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered by intravenous injection or catheter delivery.

### Claim 5 (depends on 2)

The method of claim 2, wherein the composition is administered by intravenous injection or catheter delivery.

### Claim 6 (depends on 3)

The method of claim 3, wherein the composition is administered by intravenous injection or catheter delivery.

### Claim 7 (depends on 1)

The method of claim 1, wherein the recombinant polypeptide is a fusion protein comprising the amino acid sequence of p1978 (SEQ ID NO: 1) and a heterologous polypeptide sequence.

### Claim 8 (depends on 1)

The method of claim 1, wherein the recombinant polypeptide is no more than 50 amino acids in length.

### Claim 9 (depends on 1)

The method of claim 1, wherein the recombinant polypeptide is no more than 20 amino acids in length.

### Claim 10 (depends on 1)

The method of claim 1, wherein the N-terminus, the C-terminus or both are blocked.